These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38743411)

  • 21. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.
    Suzuki K; Dimopoulos MA; Takezako N; Okamoto S; Shinagawa A; Matsumoto M; Kosugi H; Yoon SS; Huang SY; Qin X; Qi M; Iida S
    Blood Cancer J; 2018 May; 8(4):41. PubMed ID: 29712896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lotus japonicus CASTOR and POLLUX are ion channels essential for perinuclear calcium spiking in legume root endosymbiosis.
    Charpentier M; Bredemeier R; Wanner G; Takeda N; Schleiff E; Parniske M
    Plant Cell; 2008 Dec; 20(12):3467-79. PubMed ID: 19106374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daratumumab plus lenalidomide and dexamethasone
    Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
    Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daratumumab plus bortezomib and dexamethasone
    Spencer A; Lentzsch S; Weisel K; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin MD; Bosi A; Hungria V; Cavo M; Lee JJ; Nooka AK; Quach H; Lee C; Barreto W; Corradini P; Min CK; Scott EC; Chanan-Khan AA; Horvath N; Capra M; Beksac M; Ovilla R; Jo JC; Shin HJ; Sonneveld P; Soong D; Casneuf T; Chiu C; Amin H; Qi M; Thiyagarajah P; Sasser AK; Schecter JM; Mateos MV
    Haematologica; 2018 Dec; 103(12):2079-2087. PubMed ID: 30237264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erratum: Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
    Blood; 2016 Aug; 128(7):1020. PubMed ID: 31265505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erratum: Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
    Blood; 2016 Mar; 127(9):1213. PubMed ID: 31265500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
    Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
    Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
    Weisel K; Spencer A; Lentzsch S; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin MD; Bosi A; Hungria V; Cavo M; Lee JJ; Nooka A; Quach H; Munder M; Lee C; Barreto W; Corradini P; Min CK; Chanan-Khan AA; Horvath N; Capra M; Beksac M; Ovilla R; Jo JC; Shin HJ; Sonneveld P; Casneuf T; DeAngelis N; Amin H; Ukropec J; Kobos R; Mateos MV
    J Hematol Oncol; 2020 Aug; 13(1):115. PubMed ID: 32819447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.
    Hungria V; Beksac M; Weisel KC; Nooka AK; Masszi T; Spicka I; Munder M; Mateos MV; Mark TM; Qi M; Qin X; Fastenau J; Spencer A; Sonneveld P; Garvin W; Renaud T; Gries KS
    Br J Haematol; 2021 May; 193(3):561-569. PubMed ID: 33555030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
    Weisel K; Martin T; Krishnan A; Jagannath S; Londhe A; Nair S; Diels J; Vogel M; Schecter JM; Banerjee A; Berdeja JG; Nesheiwat T; Garrett A; Qi K; Valluri S; Usmani SZ; Yong K
    Clin Drug Investig; 2022 Jan; 42(1):29-41. PubMed ID: 34822128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic antibodies for multiple myeloma.
    Ishida T
    Jpn J Clin Oncol; 2018 Nov; 48(11):957-963. PubMed ID: 30329116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Komarnicki M; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Lisby S; Khokhar NZ; O'Rourke L; Chiu C; Qin X; Guckert M; Ahmadi T; Moreau P;
    N Engl J Med; 2016 Oct; 375(14):1319-1331. PubMed ID: 27705267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016.
    Terpos E;
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):329-339. PubMed ID: 28462890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
    Bahlis NJ; Dimopoulos MA; White DJ; Benboubker L; Cook G; Leiba M; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Krevvata M; Chiu C; Qin X; Okonkwo L; Trivedi S; Ukropec J; Qi M; San-Miguel J
    Leukemia; 2020 Jul; 34(7):1875-1884. PubMed ID: 32001798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
    Mateos MV; Sonneveld P; Hungria V; Nooka AK; Estell JA; Barreto W; Corradini P; Min CK; Medvedova E; Weisel K; Chiu C; Schecter JM; Amin H; Qin X; Ukropec J; Kobos R; Spencer A
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):509-518. PubMed ID: 32482541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
    Maiese EM; Ainsworth C; Le Moine JG; Ahdesmäki O; Bell J; Hawe E
    Clin Ther; 2018 Mar; 40(3):480-494.e23. PubMed ID: 29500140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.
    Wong XY; Chng WJ; Aziz MIA; Ng K
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):207-215. PubMed ID: 34904498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 39. Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
    Richter J; Lin PL; Garcia-Horton V; Guyot P; Singh E; Zhou ZY; Sievert M; Taiji R
    Cancer Med; 2023 Apr; 12(7):8005-8017. PubMed ID: 36726287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
    Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; van de Donk NWCJ; Katodritou E; Schjesvold F; Balari AS; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; Lonergan S; Ahmadi T; Liu Y; Wang J; Vieyra D; van Brummelen EMJ; Vanquickelberghe V; Sitthi-Amorn A; de Boer CJ; Carson R; Rodriguez-Otero P; Bladé J; Moreau P
    Future Oncol; 2024 Sep; ():1-21. PubMed ID: 39287147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.